CNS-Penetrant Bruton’s Tyrosine Kinase Inhibitor (BTKi) Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis: Phase 3 Clinical & MRI Outcomes
Study Design & Technical Specifications
Sample Size / Cohort
1,131 Non-Relapsing SPMS Patients
Subject / Study Model
Human Clinical Cohort
Analytical Modalities
Executive Research Summary
AI SummaryPrimary Abstract & Repository Description
Source: Europe PMCEditorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
Primary Premise (Europe PMC): "Randomized Phase 3 trial evaluating blood-brain barrier-penetrant BTK inhibition targeting both intrathecal B lymphocytes and Fc-gamma receptor-activated microglia within paramagnetic rim lesions, significantly delaying 6-month confirmed disability accumulation (CDA) on EDSS." Within Multiple Sclerosis (MS), this work examines Multiple Sclerosis, BTK Inhibitor, PIRA, EDSS, PRL in relation to paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Authored by Fox RJ, Reich DS, Oh J.
2. Study Architecture & Findings
Study Architecture: Human Clinical Cohort (1,131 Non-Relapsing SPMS Patients) utilizing Clinical Trial Endpoints, EDSS, PRL / 3T MRI, Serum NfL & GFAP [DOI: 10.1056/NEJMoa2408912]. Key reported conclusion: "Randomized Phase 3 trial evaluating blood-brain barrier-penetrant BTK inhibition targeting both intrathecal B lymphocytes and Fc-gamma receptor-activated microglia within paramagnetic rim lesions, significantly delaying 6-month confirmed disability accumulation (CDA) on EDSS."
3. Secondary Analysis & Reusability
Secondary Analysis Applications: (1) Cross-referencing Clinical Trial Endpoints, EDSS, PRL / 3T MRI, Serum NfL & GFAP variables (Multiple Sclerosis, BTK Inhibitor, PIRA, EDSS, PRL) against open repositories in Multiple Sclerosis (MS); (2) Benchmarking feature distributions and effect sizes reported in "CNS-Penetrant Bruton’s Tyrosine Kinase Inhibitor (BTKi) Tolebrutinib in Non-Rela"; (3) Informing cohort stratification and endpoint selection.
4. Methodological Caveats & Governance
Methodological Note: When integrating these Clinical Trial Endpoints, EDSS, PRL / 3T MRI, Serum NfL & GFAP findings, account for cohort-specific inclusion criteria (1,131 Non-Relapsing SPMS Patients), potential site/instrument batch effects, and repository license terms (Open Access / CC-BY).
Data Access, Reproducibility & Analysis Starter Guide
BIDS (Brain Imaging Data Structure) v1.9+
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.
Tags & Modalities
Related Multiple Sclerosis Research & Datasets
Explore All DatasetsMSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis
The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.
MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)
A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.
Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».
Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.
Active Clinical Trials & Pipeline in Multiple Sclerosis
View Clinical PipelineMSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
MSDA: GDSI Mock DataGenerator - GDSI Mock data generator
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.